Sophia Genetics has achieved another significant milestone. Today, the startup announces that it has joined forces with Illumina, the global leader in DNA sequencing technology. The two companies have signed co-marketing Agreement to speed up the adoption of Next-Generation Sequencing (NGS) in clinical diagnostics.
Sophia Genetic’s new partner, Illumina, is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina is also recognised for its integrated solutions that advance the understanding of genetics and health. Last year it generated over $2.2 billion revenue.
The collaboration with Sophia will enable the two companies to co-market their respective products and solutions to accelerate the adoption of next-generation DNA Sequencing (NGS) technologies by hospitals and laboratories for patients’ clinical diagnosis. Under the agreement, the two parties will kick-off the collaboration with joint marketing programs in EMEA.
Jurgi Camblong, CEO and co-founder of Sophia Genetics said, “We are very pleased to enter into this agreement with Illumina to speed the adoption of NGS in clinical diagnostics. Today’s agreement with Illumina underlines the value of state-of-the-art analytical solutions in routine diagnostics which truly unlock the promises of data-driven medicine for patients around the world.”
The new co-marketing arrangement will first cover the EMEA region, where Sophia Genetics and Illumina will help more hospitals and laboratories engaged in diagnostics transition to NGS and rapidly get faster, easier and more accurate results for their patients’ clinical diagnosis.
(RAN)
Please login or sign up to comment.
Commenting guidelines